Boardroom Alpha
Start trial
8-K primary document
LFWD · Current Report (Form 8-K) · Filed March 25, 2026

Lifeward Ltd — 8-K exhibit

exhibit_2-2.htm
Lifeward Ltd on Boardroom Alpha
Exhibit 2.2

ASSIGNMENT OF SHARE PURCHASE AGREEMENT

This Assignment of Share Purchase Agreement (the “Assignment”) is made and entered into to be effective as of [      ], 2026 (“Effective Date”), by and between Oratech Pharma, Inc., a Nevada corporation (“Assignor”), and Oratech Ltd., a Company limited by shares organized under the laws of the State of Israel (the “Assignee”) and acknowledged by Lifeward Ltd., a company limited by shares organized under the laws of the State of Israel (“Parent”) and Oramed Pharmaceuticals Inc., a Delaware corporation (the “Seller”).
 
RECITALS
 
A.          Assignor is a party to that certain Share Purchase Agreement, dated January 12, 2026 between the Parent, Company and Seller (the “Purchase Agreement”).
 
B.          Assignor desires to transfer and assign to Assignee, and Assignee desires to acquire, all of Assignor’s right, title and interest in and to the Purchase Agreement; subject, however, to all of the terms, conditions and obligations contained in the Purchase Agreement.
 
NOW, THEREFORE, for and in consideration of assuming the obligations contained in the Purchase Agreement and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, Assignor and Assignee hereto do hereby agree as follows:
 
AGREEMENT
 
1.          Assignment and Assumption.  Assignor does hereby sell, assign and transfer to Assignee all of Assignor’s right, title and interest in and to the Purchase Agreement.  Assignee hereby assumes and agrees to perform all of Assignor’s obligations under the Purchase Agreement, subject to the terms and conditions thereof, to the same extent as if Assignee had originally been named as “Company” therein.
 
2.          Defined Terms.  Except as may be otherwise provided herein, all defined terms used herein shall have the same meaning ascribed to them in the Purchase Agreement.
 
3.          Successors and Assigns.  This Assignment shall be binding upon and inure to the benefit of the parties hereto and their respective successors and assigns.
 
4.          Counterparts.  This Assignment may be executed in any number of counterparts with the same effect as if all parties hereto had signed the same document.  All such counterparts shall be construed together and shall constitute one instrument, but in seeking proof hereof, it shall only be necessary to produce one such counterpart.
 
This Assignment is executed by Assignor and Assignee and acknowledged by Parent and Seller as of the Effective Date referenced above.

[Remainder of Page Intentionally Left Blank]

IN WITNESS WHEREOF, the parties have caused this Assignment to be executed as of the date first above written.
 
ASSIGNOR:
 
ORATECH PHARMA, INC.

By:       _________________________________
Name:  Nadav Kidron
Title:    Chief Executive Officer

 
ASSIGNEE:
 
ORATECH LTD.

By:       _________________________________
Name:  Nadav Kidron
Title:    Chief Executive Officer

ACKNOWLEDGED BY:

LIFEWARD LTD

By:       _________________________________
Name:  William Mark Grant
Title:    President and Chief Executive Officer


ORAMED PHARMACEUTICALS INC.
By:         _________________________________
Name:   Nadav Kidron
Title:     Chief Executive Officer

Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer